With the discovery that many relapsed/refractory pLGGs have activation of mTOR pathway more treatment options may be possible for patients, including everolimus, a brain-penetrant drug already approved by the FDA for the treatment of SEGA in children (Table 3) (184, 190, 203, 204, 208–210). The gene discussed is MTOR; the disease is subependymal giant cell astrocytoma.